Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Ibrutinib
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ibrutinib 140mg capsules
0801050BSAAAAAA
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Ibrutinib 140mg tablets
0801050BSAAABAB
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Ibrutinib 280mg tablets
0801050BSAAACAC
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Ibrutinib 420mg tablets
0801050BSAAADAD
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Ibrutinib 560mg tablets
0801050BSAAAEAE
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Imbruvica 140mg capsules
0801050BSBBAAAA
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Imbruvica 140mg tablets
0801050BSBBABAB
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Imbruvica 280mg tablets
0801050BSBBACAC
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Imbruvica 420mg tablets
0801050BSBBADAD
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Imbruvica 560mg tablets
0801050BSBBAEAE
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.